Generic Name and Formulations:
Tasimelteon 20mg; hard gel caps.
Vanda Pharmaceuticals, Inc.
Indications for HETLIOZ:
Treatment of non-24-hour sleep-wake disorder (Non-24).
Swallow whole. Take 20mg once daily before bedtime, at the same time every night. Do not take with food.
Risk of somnolence; can potentially impair the performance of activities requiring mental alertness. Severe hepatic impairment (Child-Pugh C): not recommended. Smokers. Elderly. Pregnancy (Cat. C). Nursing mothers.
Melatonin receptor agonist.
Avoid concomitant strong CYP1A2 inhibitors (eg, fluvoxamine), strong CYP3A4 inhibitors (eg, ketoconazole), or others; effects may be increased. Avoid concomitant strong CYP3A4 inducers (eg, rifampin) or others; effects may be reduced. Tasimelteon exposure decreased by smoking (induction of CYP1A2 levels). Additive effects with alcohol.
Headache, increased ALT, nightmares or unusual dreams, upper respiratory tract infection, urinary tract infection; somnolence.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage